The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...

Sarepta stock crashed Friday — wiping out all of its restructuring-tied gains — after a third recipient of one of its gene therapies died.

According to multiple reports, a 51-year-old man with limb-girdle muscular dystrophy died from acute liver failure after ...

Sarepta Therapeutics Inc. said another patient has died from acute liver failure after receiving one of its gene therapies, putting additional pressure on the biotech company after the recent deaths ...

The Purdy family shares their insights on navigating their child’s rare neurodegenerative disease and their direct ...

Shares of Sarepta Therapeutics declined 17% in early trading on Friday after a patient who had received one of the company's experimental gene therapies died, deepening investor concern over the use ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and gene therapy.

The patient, who was being treated with an investigational gene therapy for limb-girdle muscular dystrophy, died of acute ...

Lab study findings increase understanding of the molecular mechanisms underpinning vitamin D deficiency and highlight SDR42E1 ...

These were the most active stocks ahead of Friday's market open: Sarepta Therapeutics Inc.'s stock tumbled 27% after the company said another patient died following gene-therapy treatment, Bloomberg ...